China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
Takeda announced that the National Medical Products Administration (NMPA) of China approved Exkivity (mobocertinib) for treating adults...
China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
Deals and Acquisitions | 2023 | Pharma | News | Healthcare | iPharmaCenter
Pharmaceutical Companies Deals and acquisitions | Sanofi | Amgen | Pfizer | 2022 | iPharmaCenter
HAS ASSESSMENT OUTCOMES | FRANCE PHARMA NEWS | médicament nouvelles | 2023 | iPharmaCenter
How is AbbVie bracing for the impact of Humira’s biosimilars? | iPharmaCenter
TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022
Saudi Arabia | Healthcare System | Drug approvals and pricing | iPharmaCenter
MEXICO HEALTHCARE SYSTEM | DRUG PRICING AND REIMBURSEMENT IN MEXICO | NEWS | BLOGS | iPharmaCenter
INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER
HEALTHCARE SYSTEM IN CHINA
Drug pricing and reimbursement in Germany | Health Technology Assessment in Germany
Why the cost of prescription drugs is high in the US?